Regulus Therapeutics Inc.
RGLS
Rang in Aktien
#17340
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Aktienkurs
$8.16
Zuletzt synchronisiert: 2025-06-26
Marktkapitalisierung
$234.57M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
-88.86%
Land
US
Handel Regulus Therapeutics Inc. (RGLS)
Kategorie
Healthcare
Dividendenrendite-Verlauf für Regulus Therapeutics Inc. (RGLS)
Dividendenrendite (TTM) von Regulus Therapeutics Inc. (Aktienkürzel: RGLS) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für Regulus Therapeutics Inc. (RGLS) von 2026 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
| Jahr | Dividendenrendite | ändert |
|---|---|---|
| Nicht genügend Daten für die angegebenen Daten. | ||
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | Dividendenrendite | Land |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
